People who do not suffer from any disability often take for granted the ability to freely move limbs. However, the loss of such an ability is devastating, and those to whom it happens to find life is never the same again. At least, that is the case without treatment. The good news is, paralysis may have the hope of treatment after all, in the form of stem cells. [Read more…]
Cellular Engineering Technologies Receives Exclusivity to Use John Paul II Medical Research Institute’s Immortalized Human Stem Cells for Commercial Bio-Production Applications
The exclusive right grants Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize next generation bio-production of recombinant proteins, viral vectors for gene therapy and vaccines with a more native human post-translational modification (PTM).
BELIEVER Meats Breaks Ground on Largest Cultivated Meat Production Facility in The World
-
The company’s first U.S. commercial scale production facility is planned at 200,000 square feet, with possible expansion in the future
-
Once fully operational, the facility’s production capacity will be at least 10,000 metric tons (22 million pounds)
-
The project represents an initial planned investment of $123.35 million in Wilson County, North Carolina
Ryne Biotechnology Wins $4M from CIRM to Develop RNDP-001, an iPSC-Derived Dopamine Neuron Progenitor
February 14, 2023, San Diego, California — Ryne Biotechnology, Inc. (Ryne Bio), a therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological disorders, announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4 million Clinical Stage Research Program (CLIN1) grant. This funding will enable the company to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application within the next 12 months. [Read more…]
Heartseed and Novo Nordisk Dose First Patient with HS-001, an iPSC-Derived Cell Therapy to Treat Heart Failure
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).
Clinical phase 1/2 study (LAPiS Study) will enroll 10 patients with advanced heart failure caused by ischaemic heart disease.
Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. [Read more…]
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 201
- Next Page »